Drugs / MSP008-22
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05478486 | Feb 2023 → Jan 2026 | neoplasm | Godavari Biorefineries Limited | Completed | No outcome recorded |
| Phase 1 | NCT05532293 | Dec 2022 → Nov 2025 | COVID-19 | Godavari Biorefineries Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSP008-22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05532293 ↗ |
| Modality | Small molecule | “MSP008-22 is a small molecule” NCT05532293 ↗ |
| Route | Oral | “single oral ascending doses” NCT05478486 ↗ |